Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ: EXAS), a leading cancer screening and diagnostic tests provider, has announced its participation in the upcoming William Blair 45th Annual Growth Stock Conference in Chicago. The company's management will deliver a presentation on Tuesday, June 3, 2025, at 9:40 a.m. ET. Investors can access the webcast through the investor relations section of Exact Sciences' website.

The Oncodetect™ molecular residual disease (MRD) test shows promising results from the Beta-CORRECT study for stage II-IV colorectal cancer patients. A partnership with Flatiron Health continues enrollment for evaluating MRD testing across multiple solid tumors.

Their multi-cancer early detection (MCED) research reveals potential to reduce late-stage cancer incidence by >40% and mortality by up to 18% in high-risk groups. The company plans to launch Cancerguard™ EX, their MCED lab-developed test, in H2 2025.

The presentation will also feature new data on the Oncotype DX Breast Recurrence Score® test and Cologuard® test, reinforcing their role in cancer screening and treatment decisions. The Falcon registry study will track 25,000 participants against 50,000 standard-care patients to assess MCED test outcomes.

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, has announced its upcoming participation in the BofA Securities Health Care Conference in Las Vegas. Company management will engage in a fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 p.m. ET (10:40 a.m. PT). Investors can access the webcast through the investor relations section of Exact Sciences' website at www.exactsciences.com.

Exact Sciences (NASDAQ: EXAS) reported strong Q1 2025 results with total revenue of $707 million, up 11% year-over-year. The company's Screening revenue grew 14% to $540 million, while Precision Oncology revenue increased 2% to $167 million. Despite progress, the company posted a net loss of $101 million ($0.54 per share).

Key developments include the launch of Cologuard Plus™, a next-generation colon cancer screening test with improved sensitivity and 40% fewer false positives, and Oncodetect™, a molecular residual disease test. The company raised its full-year 2025 guidance, increasing revenue outlook to $3.070-$3.120 billion and adjusted EBITDA to $425-$455 million.

Exact Sciences (NASDAQ: EXAS) will present 15 research abstracts at Digestive Disease Week (DDW) 2025 in San Diego, showcasing data about their Cologuard® colorectal cancer screening test. The presentations will highlight:

• High adherence rates across diverse demographics
• Strong predicted patient preference for Cologuard
• Data from over 500,000 patients
• Research on screening programs under development

The company will host booth sessions led by Jordan Karlitz, discussing CRC screening assumptions and early detection importance. Key research topics include patient test preferences, follow-up colonoscopy adherence patterns, and screening effectiveness across different racial/ethnic groups and healthcare settings. The presentations also include studies on environmental impact and a non-endoscopic Barrett's Esophagus detection test.

Exact Sciences (NASDAQ: EXAS) has launched Oncodetect™, a new molecular residual disease (MRD) test for multiple solid tumors. The test can detect cancer recurrence up to two years earlier than imaging by identifying up to 200 ctDNA variants.

Key features of the Oncodetect test include:

• Ability to detect 1 ctDNA molecule in 20,000 cfDNA molecules
• Provides clear 'Detected' or 'Not Detected' results with quantitative data
• Patients testing positive are 50 times more likely to experience cancer recurrence

The test is validated through the Alpha-CORRECT study with nearly five years of follow-up data for colorectal cancer recurrence. Exact Sciences is working with Medicare for reimbursement coverage and advancing validation studies across multiple solid tumors. The test is now available and targets a potential market of over 3 million eligible American patients.

Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, has scheduled its first quarter 2025 earnings release for May 1, 2025, after U.S. market close. The company will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

The live webcast will be accessible through www.exactsciences.com. Domestic callers can dial 888-330-2384, while international callers should use +1 240-789-2701. Both domestic and international callers will need to use access code 4437608. A replay of the webcast will be made available on the company's website.

Exact Sciences (NASDAQ: EXAS) has launched Cologuard Plus™, a groundbreaking colorectal cancer screening test demonstrating 95% sensitivity for cancer detection at 94% specificity - making it the most accurate noninvasive screening option to date.

The FDA-approved test shows significant improvements over its predecessor, including up to 40% reduction in unnecessary follow-up colonoscopies compared to the original Cologuard® test. Key features include 43% sensitivity for advanced precancerous lesions and 74% sensitivity for high-grade dysplasia. The test maintains a 99.98% negative predictive value.

Building on Cologuard's success of over 19 million screenings in the past decade, the new test is backed by the 20,000+ person BLUE-C study published in the New England Journal of Medicine. The test is covered by Medicare, included in USPSTF guidelines, and maintains strong patient adherence with 71% completion rate within 28 days.